Home Newsfeeds Bernstein Downgrades Vodafone Group to Market Perform

Bernstein Downgrades Vodafone Group to Market Perform

Bernstein analyst Stan Noel downgrades Vodafone Group (NASDAQ:VOD) from Outperform to Market Perform.

byBenzinga Newsdesk

August 1, 2022

1 minute read

Bernstein analyst Stan Noel downgrades Vodafone Group (NASDAQ:VOD) from Outperform to Market Perform.

Lightspeed Commerce’s Q1 Earnings Top Estimates On Substantial Gross Payments Volume Growth; Backs FY24 Forecast

By Nabaparna Bhattacharya

August 3, 1:37 PM

Lightspeed Commerce Inc. (NYSE: LSPD) reported first-quarter FY24 revenue growth of 20.2% year-over-year to $209.09 million,

LSPD

News

Vistagen Announces Results Of Voting From 2022 Annual Meeting Of Stockholders And Partial Adjournment To October 28, 2022

By Benzinga Newsdesk

October 19, 4:45 PM

Annual Meeting to resume October 28, 2022 to vote on Proposal No. 5 to provide Vistagen's Board of Directors the option to implement a future reverse stock split of the Company's issued and outstanding common

VTGN

Weight Loss Drug Competition – FDA Approves Expanded Use Of Eli Lilly’s Blockbuster Tirzepatide For Weight Loss, Undercutting Novo Nordisk’s Price

By Vandana Singh

November 8, 3:04 PM

The FDA has approved

LLY

DBV Technologies Advances Peanut Allergy Program With FDA Support On Pediatric Studies

By Vandana Singh

August 1, 9:29 AM

DBV Technologies (NASDAQ: DBVT) received Type C meeting written responses from the FDA on key study design elements for the COMFORT Toddlers and COMFORT Children supplemental safety studies in 1 – 3-year-olds and 4 – 7-year-olds,

DBVT

Bernstein Downgrades Vodafone Group to Market Perform

Related Posts

Lightspeed Commerce’s Q1 Earnings Top Estimates On Substantial Gross Payments Volume Growth; Backs FY24 Forecast

Vistagen Announces Results Of Voting From 2022 Annual Meeting Of Stockholders And Partial Adjournment To October 28, 2022

Weight Loss Drug Competition – FDA Approves Expanded Use Of Eli Lilly’s Blockbuster Tirzepatide For Weight Loss, Undercutting Novo Nordisk’s Price

DBV Technologies Advances Peanut Allergy Program With FDA Support On Pediatric Studies